La Jolla Pharmaceutical (LJPC) Tops Q1 EPS by 9c
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
La Jolla Pharmaceutical (NASDAQ: LJPC) reported Q1 EPS of ($0.90), $0.09 better than the analyst estimate of ($0.99).
As of June 30, 2016, La Jolla had $100.6 million in cash and cash equivalents, compared to $126.5 million as of December 31, 2015. The decrease in cash and cash equivalents was primarily due to net cash used for operating activities. Based on current operating plans and projections, La Jolla believes that its current cash and cash equivalents are sufficient to fund operations into 2018.
For earnings history and earnings-related data on La Jolla Pharmaceutical (LJPC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Gold (ABX) Tops Q3 EPS by 4c
- Spok Holdings (SPOK) Reports Q3 EPS of $0.20
- Antero Midstream Partners (AM) Tops Q3 EPS by 5c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!